Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Available-for-Sale Securities (Non-Current)

Available-for-Sale Securities (Non-Current) at other companies

Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
——

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesNoncurrent.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s available-for-sale securities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s available-for-sale securities (non-current)?
Denali Therapeutics Inc. (DNLI) reported available-for-sale securities (non-current) of $63.79M in Q1 2026.
How has Denali Therapeutics Inc.'s available-for-sale securities (non-current) changed year-over-year?
Denali Therapeutics Inc.'s available-for-sale securities (non-current) decreased by 73.0% year-over-year, from $235.84M to $63.79M.
What is the long-term trend for Denali Therapeutics Inc.'s available-for-sale securities (non-current)?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s available-for-sale securities (non-current) has grown at a 24.6% compound annual growth rate (CAGR), from $32.7M to $98.32M.